FOSUN PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

make any statement and expressly disclaim any liability for any damages whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

assumes no responsibility for any failure.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 02196)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to set forth the "About

Announcement on the Implementation Progress of Equity Incentives of Controlled Subsidiaries and Related Transactions" is for reference only.

By order of the board of directors Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Chairman

Chen Yuqing

China, Shanghai

June 15, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the Company The non-executive directors of the company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the company are Mr. Yu Zishan, Mr. Wang Quandi, and Mr. Chen Mr. Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

*For identification only

Securities code: 600196 Securities abbreviation: Fosun Pharma Announcement number: Lin 2026-083

Shanghai Shanghai Fufu Xingxing Medical and Pharmaceutical ((Group)) Co., Ltd.

Regarding the progress of the implementation of equity incentives in controlling subsidiaries

and announcements related to related party transactions

The Board of Directors of the Company and all directors hereby certify that the contents of this announcement do not contain any false records or misleading statements.

The statements may contain many omissions or omissions, and we shall be legally responsible for the truthfulness, accuracy and completeness of its contents. .

Important content reminders

●● Overview::

In August 2024, its holding subsidiary Fosun Entkin adopted the second phase of the incentive plan; based on this plan,

Fosun Antjin can grant up to 756,947 restricted equity shares (corresponding to 756,947 Fosun Antjin shares

portions). The program was revised and first awarded in January 2026. On June 15, 2026, with the approval of the Board of Directors of the Company and its holding subsidiary Fosun Entejin, the same

intends to make the second grant of the plan (i.e., this grant), which will be made by Fosun Antkin at 25.26 yuan/1 share

At the price of the restricted equity, 111,000 restricted equity (corresponding to 111,000 complex shares) was granted to Mr. Chen Zhanyu.

Star Ant Gold Shares); Based on this grant, the incentive object will indirectly hold the partnership share of the incentive platform.

Holds shares of Fosun Entejin. The shares of Fosun Antkin involved in this grant are existing shares. Failure to consider other possible causes of Fosun Antkin

Factors that change the ownership structure: Before and after this grant, the holding subsidiary Fosun Pharmaceutical Industry held Fosun Entejin

The shareholding ratio remains unchanged.

●Since the incentives granted this time are senior managers of the Company, according to the Listing Rules of the Shanghai Stock Exchange,

It constitutes a related party of the Company, and this grant constitutes a related transaction of the Company. ●This related transaction has been reviewed and approved at the 32nd meeting of the 10th Board of Directors of the Company, and no mention is required.

The shareholders' meeting is requested to approve.

11. An overview of the plan and implementation of the existing stock equity incentive plan of Fuxing Ante Gold

In order to effectively attract and retain companies that have an important influence and contribution to the business growth of Fosun Entjin and its holding subsidiaries, We will contribute core talents to inspire entrepreneurial passion and help the company's long-term development. On August 27, 2024, the company

The board of directors/shareholders meeting of the company and its holding subsidiary Fosun Antjin respectively approved the new issuance of Fosun Antjin

The registered capital of 3.19724 million yuan (i.e. 3.197240 Fosun Antjin shares) is used to implement equity in installments.

Inspire. Immediately before this award, Fosun Entkin has implemented two phases of incentive plans, and the progress is as follows:

1. Based on the first phase of the incentive plan, Fosun Antjin has provided incentives to eligible incentive targets (including some A total of 2,440,293 restricted equity shares (corresponding to directors and senior managers of Fosun Pharma) were granted

2,440,293 shares of Fosun Antkin). For details, please see our company August 28, 2024, 2026

On January 15, 2019, it was published in China Securities Journal, Shanghai Securities News, Securities Times and the website of the Shanghai Stock Exchange.

Relevant announcements issued by (https://www.sse.com.cn).

2. Based on the second phase of the incentive plan, Fosun Antjin has provided incentives to eligible incentive targets (not involving complex Directors and senior managers of Xing Pharmaceutical) made the first grant; immediately before this grant, awards had been made under this phase of the plan.

A total of 645,947 issued and valid restricted equity shares (corresponding to 645,947 Fosun Antjin shares),

There are still 111,000 restricted equity shares (corresponding to 111,000 Fosun Entejin shares) available for subsequent grant

(Including this award).

22. Overview of the Grant and Related Related Party Transactions

According to the second phase of Fosun Ant Gold Incentive Plan, on June 15, 2026, through the Company and Fosun Ant Gold

The Board of Directors separately approved that Fosun Antkin would make the second grant of the plan (i.e., "the Grant").

That is, 111,000 restricted equity shares (corresponding to 111,000 Fosun Entejin shares) were granted to Mr. Chen Zhanyu;

Based on this grant, the incentive object will indirectly hold shares of Fosun Ant Gold through holding partnership shares of the incentive platform.

portion. The price granted this time is 25.26 yuan/1 restricted equity. According to this incentive plan, this award

The grant price is determined based on the higher of the following prices: (1) the first grant price plus the first grant incentive object is awarded

The period from the restricted equity to the date of this grant (i.e. the date when Fosun Antkin’s board of directors agrees to this grant, the same below)

Bank loan interest during the same period (i.e. 20.86 yuan/share), (2) Fosun Antjin’s latest fair price per share 1 3

discount (i.e. 25.26 yuan/share).

1 is the price of capital increase and share expansion in June 2026, the same below.

The shares of Fosun Antkin involved in this grant are existing shares. Failure to consider other possible causes of Fosun Antkin

Factors that change the ownership structure: Before and after this grant, the holding subsidiary Fosun Pharmaceutical Industry held Fosun Entejin

The shareholding ratio remains unchanged.

Since the incentives granted this time are senior managers of the Company, according to the Listing Rules of the Shanghai Stock Exchange, It constitutes a related party of the Company, and this grant constitutes a related transaction of the Company.

This grant (i.e., this related transaction) has been reviewed at the 32nd meeting of the 10th Board of Directors of the Company.

Passed and approved in advance by a special meeting of independent non-executive directors.

As of this related transaction, in the past 12 months, unless approved by the shareholders’ meeting and in accordance with relevant rules,

Except for the related transactions that are exempt from the approval of the shareholders' meeting individually or cumulatively, the related transactions between the Group and the related parties have not been Reaching 5% of the Group’s latest audited net assets attributable to shareholders of listed companies, the Group has

The related-party transactions related to the types of transactions between the parties have also not reached the level of the Group's most recent audited listing.

5% of the company's shareholders' net assets. This related transaction does not need to be approved by the company's shareholders' meeting.

33. Basic information about related parties

Related person’s name: Chen Zhanyu Senior Vice President of Fosun Pharma, Co-Chairman of Vaccine Division, Fosun Ant Current main duties Kim COO Whether he is the person subject to execution for dishonesty Yes √No Note □Controlling shareholders, actual controllers and persons acting in concert

Type of related relationship √ Dong Gao of listed company □Others The subject matter of the transaction is 111,000 restricted shares (corresponding to 111,000 shares of Fosun Antkin).

Transaction consideration 2.80386 million yuan Note: Based on the query results of China Execution Information Disclosure Network.

44. The basic situation of the restored star Anantetkin.

((11)) Overview

Fosun Entejin was established in July 2012 and changed to a joint stock limited company in January 2026. complex

Xingantejin and its holding subsidiaries mainly focus on attenuation/inactivation technology, polysaccharide/binding technology, and recombinant protein technology.

The technology platform is engaged in the research, development, production and sales of vaccines. As of the date of this announcement, June 15, 2026, The same below), its independently developed human rabies vaccine (Vero cells), freeze-dried human rabies vaccine (Vero

Cells), trivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine and other products have been sold in China.

was approved for marketing; its independently developed 13-valent pneumococcal polysaccharide conjugate vaccine and freeze-dried human rabies vaccine

(human diploid cells) are in phase III clinical trials in China and 24-valent pneumococcal polypeptide. The glycoconjugated vaccine is in phase I clinical trials in China, and the 23-valent pneumococcal polysaccharide vaccine has also been

Obtained clinical trial approval in China.

((22)) Specific information

Legal person/organization name Fosun Entgene (Chengdu) Biopharmaceutical Co., Ltd. Unified social credit code 915101000500674063

Whether it is a subsidiary within the consolidation scope of a listed company √Yes □No Is this transaction Yes √No Resulting in changes in the scope of consolidated statements of listed companies Date of establishment 2012/07/06 Registered address: Tianfu International Biocity, Chengdu, Sichuan Province

Legal representative Wang Kexin The registered capital as of the date of this announcement is RMB 83,128,249 (fully paid in)

Licensed items: pharmaceutical production; pharmaceutical commissioned production; pharmaceutical import and export Port; general projects: medical research and experimental development; technical services, Main business Technology development, technology consulting, technology exchange, technology transfer, technology Extension; information technology consulting services; medical research and experimental development. Industry C276 Biological pharmaceutical products manufacturing

((33)) The situation of capital increase, capital increase, restructuring and restructuring in the past 1122 months

1. In January 2026, Fosun Entejin was changed from a limited liability company to a joint stock company and changed its name.

It is "Fosun Entejin (Chengdu) Biopharmaceutical Co., Ltd.".

2. On June 15, 2026, Fosun Entjin and Fosun Pharmaceutical Industries, including the company’s controlled subsidiary (i.e. the direct controlling shareholder of Fosun Entejin) signed an agreement, (which mainly included

Including) Fosun Antkin plans to issue a total of new issuances to these investors at a price of 84.207235 yuan per share.

11,495,449 shares, of which: external investors plan to subscribe for a total of 4,963,944 shares for a total of 418 million yuan

Fosun Pharmaceutical Industries plans to subscribe for 6,531,505 new shares for RMB 550 million. Increase capital

After the share expansion is completed, the Company (through Fosun Pharmaceutical Industries) will hold 68.47% of the equity of Fosun Antjin (70.08% before capital increase and share expansion). For details, please refer to the "About Holding Subsidiaries" published on the same day as this announcement.

Announcement on Capital Increase and Share Expansion".

5. The main contents of the second phase of the Fuxing Ante Gold Incentive Plan

6. Purpose

The plan aims to effectively attract and retain those who are important to the business growth of Fosun Antkin and its holding subsidiaries.

core talents who influence and contribute, and establish a "shared sharing" that aims to align the interests of shareholders and operators mechanism to stimulate employees' entrepreneurial passion and help the company's long-term development.

2. Management

The incentive plan was reviewed and approved by Fosun Antkin’s shareholders’ meeting. The Board of Directors of Fosun Entjin, based on its shareholder

The committee will be authorized to be responsible for the formulation and implementation of the plan and its supporting documents, including but not limited to the formulation, revision, and termination of incentives.

Incentive plan plan, determination of incentive target list, grant of restricted equity and other related matters required to complete the plan matters.

3. Deadline

Unless terminated early under specified circumstances, the plan is valid from the date of adoption of the plan to the date of the incentive

The maximum period shall not exceed 10 years from the date when all restricted equity rights granted are unlocked.

4. Incentive tools and corresponding registered capital of the target company The incentive tool of this plan is restricted equity, that is, the incentive object is granted restricted equity by holding the incentive

Li Platform indirectly holds a certain amount of property shares in Fosun Antjin’s registered capital before the restricted equity is unlocked.

Incentive objects are not entitled to dividends, disposals, etc. with respect to the registered capital of Fosun Antjin held indirectly by them. Each 1 limit

The institutional equity corresponds to every 1 yuan of registered capital of Fosun Entejin.

After all the restricted equity (which can be granted in batches) involved in the plan is unlocked, the corresponding total amount will not exceed Fosun An Tejin’s registered capital is RMB 756,947 (i.e. 756,947 Fosun Antjin shares). These shares are derived from complex

Xingantejin contributes to the issued registered capital of the incentive platform.

5. Incentive objects

Incentives for this program include:

(1) Directors, supervisors and senior managers of Fosun Antjin and its holding companies and branches; (2) Key management personnel of Fosun Entjin and its holding companies and branches;

(3) Core technical personnel of Fosun Antjin and its holding companies and branches;

(4) Those who have made substantial contributions to the development of the company and have been recognized by the Board of Directors of Fosun Antkin

and other employees or personnel of its controlling companies.

6. Award price and payment arrangements

The first grant price under this plan is 20.60 yuan/1 restricted equity.

With the approval of the board of directors of Fosun Entejin, subsequent grants can be made according to the plan at the following prices (whichever is higher):

(1) The first grant price plus the first grant of restricted equity to the incentive object for the same period to the date of grant Bank loan interest, (2) 30% discount to the latest fair price per share of Fosun Antkin.

Incentive objects shall make payment within the agreed period after being granted restricted equity and completing the corresponding industrial and commercial change registration.

Pay 1 yuan/1 share of restricted equity, and pay within the agreed period after the conditions for unlocking the restricted equity are met.

Pay the remaining grant consideration.

7. Unlocking Arrangements for Restricted Equity Interests According to the plan, the Fosun Ant Gold Board of Directors confirms the corresponding assessment annual Fosun Ant Gold during each unlocking period.

The achievement of established performance milestones (such as R&D milestones, sales milestones, etc.) at the financial level and the individual incentives

The date of performance appraisal results is the performance confirmation date. Restrictions on performance confirmed to have been achieved on the performance confirmation date

The equity will be unlocked after other agreed conditions are met and the corresponding incentive objects pay all the consideration in accordance with the agreement.

66. This award is granted to

67. Grant objects and quantities

On June 15, 2026, according to the second phase of the Fosun Ant Gold Incentive Plan, the Company and Fosun Ant Gold The Board of Directors of Fosun Entjin separately approved the grant of 111,000 restricted shares to Mr. Chen Zhanyu (for

111,000 shares of Fosun Entejin); based on this grant, the incentive object will hold the incentive equalization

The Taiwanese partnership indirectly holds shares of Fosun Antkin.

2. Award price and pricing basis

The price granted this time is 25.26 yuan/1 restricted equity, which is based on the incentive plan for this period as follows: The higher price is determined: (1) The first grant price plus the first grant of restricted equity to the incentive object until this time

Bank loan interest for the same period during the grant date (i.e. 20.86 yuan/share), (2) Fosun Antjin’s latest fair share

The price is 30% off (that is, the unit price of the capital increase and share expansion in June 2026 is 84.207235 yuan/share) (that is, 25.26 yuan/share).

The discount rate of this grant price compared to Fosun Antkin’s latest fair price per share is the same as the first grant of the plan.

Consistent and similar to the biopharmaceutical companies that can be found in the past five years and are relatively comparable to Fosun Entjin. Relevant discount rates set by incentive cases using restricted equity instruments adopted and implemented before the market, details are as follows

Next:

Award price Per share Grant time Cocoa Co., Ltd. Stock Code Incentive Tools Incentive Grant Date //Award Time Grant price Fair value Fair value 2.54 yuan/share 14% restricted Green Bamboo Biotech 02480.HK April 2022 5.09 yuan/share 17.98 yuan/share 28% shares 7.19 yuan/share 40% Restricted 3.89 yuan/share 20% Tide Pharmaceutical 03880.HK November 2021 19.13 yuan/share Shares 7.30 yuan/share 38% Restricted November 2021 3.58 yuan/share 12.3135 yuan/share 29% Haina Pharmaceutical Note Share unit December 2022 3.61 yuan/share 16.5929 yuan/share 22% Note: It will submit a listing application to the Hong Kong Stock Exchange in November 2025. 3. Source of shares The source of the shares granted this time is the registered capital issued by Fosun Antkin to the incentive platform. 4. Unlocking arrangements

First time award Unlock conditions Unlock the number of unlocks that can be unlocked Cocoa unlocks period notes Fu Fu Star An Ante Gold Layers Inspiring Objects Arrangement Arrangement Percentage of Number of Grants Awarded Performance appraisal and appraisal Individual performance appraisal and appraisal The proportion upper limit of Achievement of established performance milestones within 2025 2025 personal performance appraisal results The status of the first phase was confirmed by Fosun Antkin’s board of directors and reached 33% from the date of grant. Achieve "Meets Expectations" and above Other agreed conditions Achievement of established performance milestones in 2026 2026 individual performance appraisal results from 2027 The status of the second phase was confirmed by Fosun Antkin’s board of directors and reached 33% Achieve "Meets Expectations" and above from April 1 Other agreed conditions Achievement of established performance milestones within 2027 2027 annual individual performance appraisal results from 2028 The status of the third phase was confirmed by Fosun Antkin’s board of directors and reached 34% Achieve "Meets Expectations" and above from April 1 Other agreed conditions Note: According to the plan, Fosun Entejin’s board of directors will confirm the established performance milestones (such as R&D mileage) in the corresponding assessment year during each unlocking period. (monuments, sales milestones, etc.)) and the date of the individual performance appraisal results of the incentive targets is the performance confirmation date. Confirmed on the performance confirmation date Restricted equity that achieves performance can be unlocked after other agreed conditions are met and the corresponding incentive recipients pay the full grant consideration in accordance with the agreement. 77. The impact of this sub-award on listed companies The shares of Fosun Antkin involved in this grant are existing shares. Failure to consider other possible causes of Fosun Antkin Factors that change the ownership structure: Before and after this grant, the holding subsidiary Fosun Pharmaceutical Industry held Fosun Entejin The shareholding ratio remains unchanged.

88. This award shall be subject to the review agenda procedures.

This grant (i.e., this related transaction) has been reviewed at the 32nd meeting of the 10th Board of Directors of the Company.

Passed and approved in advance by a special meeting of independent non-executive directors; this grant does not need to be submitted to the company’s shareholders’ meeting Approved.

99. Historical related party transactions

Except for this related transaction, within 12 months before the date of this announcement, there were a number of transactions between the Group and different related parties.

Related party transactions related to the types of transactions that occurred mainly include:

1. In June 2025, the holding subsidiary Fosun Pharma USA, Inc. will underwrite through underwriters

Public sale of all 2,854,607 NATR shares held; in this sale, related party NATR actually

Invested approximately US$10 million to repurchase 833,333 NATR shares held by Fosun Pharma USA, Inc.

(hereinafter referred to as "NATR Repurchase"). The sale, including the NATR repurchase, takes place in June 2025 ET

The delivery was completed on the 27th. 2. On June 30, 2025, Fosun Industrial, a holding subsidiary, signed two "Share Share Agreements" with related party NATR.

Purchase Agreement", Fosun Industrial plans to transfer to NATR for US$3.1 million and US$3.9 million respectively.

The 20% equity held by Nature's Sunshine Hong Kong Limited (hereinafter referred to as "the transfer

Natural Sunshine Hong Kong Equity"), 20% equity of Natural Sunshine (Shanghai) Daily Necessities Co., Ltd. (hereinafter referred to as

"Transfer of Natural Sunshine Shanghai Equity Interest"). As of the date of this announcement, the transfer of Natural Sunshine Hong Kong equity has been completed. The transfer and transfer of Natural Sunshine Shanghai's equity is yet to be completed.

3. On July 15, 2025, the holding subsidiary Ningbo Fuying and Suzhou Angel Investment Guidance Fund (with

Limited Partnership) and related party Xingsheng Fuying signed a "Partnership Agreement", intending to invest in the jointly invested Suzhou Angel Fund

The bank reduced its capital in the same proportion, with a total capital reduction of RMB 76 million, of which Xingsheng Fuying, a related party, reduced its subscribed capital contribution

1,295,455 yuan. As of the date of this announcement, the industrial and commercial change registration for this capital reduction has been completed. 4. On July 22, 2025, after review and approval at the fourth meeting of the tenth board of directors of the company, it was agreed

The company (or its holding subsidiary) invested RMB 120 million to participate in the establishment of Xingrui, a nuclear medicine business platform enterprise

Jingxuan, and implemented the company’s co-investment and first-phase incentive plan, including: (1) Total investment from 6 co-investors

2.1 million yuan was used to establish a new co-investment platform to subscribe for the same amount of registered capital as when Xingrui Jingxuan was established (including several senior executives of the company)

level management personnel with a total investment of RMB 1 million); and (2) after the establishment of Xingruijingxuan, adopt and implement Xingruijing

The first phase of Xuan’s equity incentive plan is to grant options to 6 incentive targets. If all these options are exercised, they will

Yingxing Ruijingxuan has a total registered capital of 4.2 million yuan (of which several senior managers of the company have been awarded a total of 200

10,000 yuan option). As of the date of this announcement, Xingrui Jingxuan and its co-investment platform have completed industrial and commercial establishment registration.

The first phase of Ruijingxuan’s equity incentive plan has been reviewed and approved by its board of directors and granted. 5. On August 5, 2025, the holding subsidiary Fosun Pharma (Shenzhen) and its related party Shenzhen Biomedicine

The industrial fund signed a "Joint Venture Contract", and Fosun Pharma (Shenzhen) and Shenzhen Biopharmaceutical Industry Fund plan to divide

In the current period, they invested RMB 100 million and RMB 400 million respectively to jointly establish and invest in Shenzhen Hengtai, accounting for 10% of Shenzhen Hengtai's investment respectively.

Thai 20% and 80% equity. As of the date of this announcement, Shenzhen Hengtai has completed industrial and commercial registration.

6. August 5, 2025, including the company’s holding company Nanjing Fund and related party Shenzhen Biomedicine The then shareholders of Shengbao Biotech, including industrial funds, jointly participated in signing the reorganization agreement, and all current shareholders of Shengbao Biotech

Dong plans to establish the Shengbao Group (i.e. Shengbao Cayman and its controlling subsidiaries including Shengbao Biotech) through equity raising.

company)’s red-chip structure. Before the reorganization (that is, as of the signing date of the reorganization agreement), the Group (through Nanjing Fund)

Holds approximately 1.8182% of the equity of Shengbao Biotech; immediately after the completion of the restructuring, the Group (through Nanjing Fund) holds

Youshengbao Cayman's shareholding ratio remains unchanged. As of the date of this announcement, the restructuring has been completed. 7. All shareholders of Jingkang Leasing (including the company’s controlled subsidiary Fosun Pingyao and related parties Shanghai Star

Xin Investment Management Co., Ltd., Fosun Golden Corona Finance Company Limited) are consistent

It was decided that Kangjian Leasing would be liquidated and cancelled, and each shareholder would be liquidated and distributed according to their shareholding ratio. 2025

In October 2020, Fosun Pingyao received a cancellation distribution payment of approximately RMB 21.8183 million from Kangjian Leasing.

8. On October 17, 2025, (1) Holding subsidiaries Fosun Carey, Fosun Pharmaceutical Industries and related parties Shenzhen Biomedical Industry Fund signed a "Capital Increase Agreement" and Shenzhen Biomedical Industry Fund plans to participate in Fosun Capital

Fosun Carey’s Series A financing, that is, it is planned to invest a total of 600 million yuan in installments and subscribe to Fosun Carey no more than the total

524.437452 million yuan of newly registered capital; (2) On the same day, Fosun Carey and directors including directors of Fosun Carey and

14 co-investment participants, including core management, and the co-investment platform Fu Ruiyi signed the "Co-investment Agreement" and "Co-investment Agreement" respectively.

Investment Platform Capital Increase Agreement" (hereinafter referred to as "Fosun Carey Co-investment"), these co-investment participants intend to A total of RMB 3.525 million was invested to subscribe for Fosun Carey’s new registered capital totaling RMB 3.08107 million, of which

Several directors and senior managers of the company contributed a total of RMB 1.246664 million to subscribe for Fosun Carey.

1.089664 million yuan of new registered capital; (3) On the same day, the company’s board of directors and Fosun Kairui shareholders’ meeting respectively

Approved the adoption and implementation of the incentive plan by Fosun Carey. According to the plan, Fosun Carey plans to use the incentive platform Fosun Carey

The students will grant incentives corresponding to the registered capital of Fosun Kairui not exceeding RMB 93,219,893 in total to the intended incentive recipients.

Equity (including restricted equity and options); of which: the first batch of grants to be granted shall not exceed 7,618.4870

Ten thousand yuan of Fosun Carey's registered capital incentive rights (hereinafter referred to as the "Fosun Carey Incentive Plan First Grant").

Among them, certain directors and senior managers of the Company were granted incentive rights in the first batch and were fully vested/resolved.

Lock, these related incentive objects can be held indirectly through Fu Ruisheng’s total investment of 9.694159 million yuan. Fosun Carey’s registered capital is RMB 12,755,472.

As of the date of this announcement, the first phase of the capital increase and the co-investment by Fosun Carey have completed the industrial and commercial change registration.

The first batch of grants under Fosun Carey’s incentive plan has been awarded.

9. On December 22, 2025, the holding subsidiary Fosun Pharmaceutical Industry and Fuyao Qihang and related parties Shanghai

Fujian signed a partnership agreement and planned to jointly invest in the establishment of Hangzhou Fuyao; among which: Shanghai Fujian planned to serve as a general partnership A person invested RMB 100,000 to subscribe for 1% of the property share of Hangzhou Fuyao; Fosun Pharmaceutical Industry and Fuyao Qihang plan to be owned

The limited partners invested 4.9 million yuan and 5 million yuan respectively to subscribe for 49% and 50% of the property shares of Hangzhou Fuyao. As of

As of the date of this announcement, Hangzhou Fuyao has completed its industrial and commercial registration.

10. On January 13, 2026, the holding subsidiary Fosun Pharmaceutical Industry and Fuyao Qihang and related parties Shanghai

Shanghai Fujian signed a partnership agreement and planned to jointly invest in the establishment of Xingyao No. 2; among which: Shanghai Fujian planned to serve as a general partnership People invested RMB 100,000 to subscribe for 1% of the property share of Xingyao No. 2; Fosun Pharmaceutical Industry and Fuyao Qihang plan to become owned

The limited partners invested 4.9 million yuan and 5 million yuan respectively to subscribe for 49% and 50% of the property shares of Xingyao No. 2. As of

As of the date of this announcement, Xingyao No. 2 has completed industrial and commercial registration.

11. On March 31, 2026, controlled subsidiaries Xingshuangjian Medical, Fosun Health and related parties Xingshuangjian

The investment signed the "Capital Reduction Agreement". Fosun Health and Stars Shuangjian Investment plan to reduce the capital of Stars Shuangjian Medical in the same proportion. The total capital reduction was RMB 60 million, of which Xingshuangjian Investment, a related party, reduced its subscribed capital contribution by RMB 29.4 million. As of

As of the date of this announcement, the capital reduction is pending industrial and commercial change registration.

12. On May 26, 2026, new investors, including its holding subsidiary Fosun Pharmaceutical Industries, entered into an

Yaokunze and its existing shareholders (including related parties Suzhou Fund and Tianjin Fund) signed the "Capital Increase and Share Transfer"

Agreement", stipulating (among other things) that Fosun Pharmaceutical Industry (1) will contribute RMB 217,813,912 to subscribe for Xingyao Kun Ze added a registered capital of RMB 2.936752 million, (2) a total investment of RMB 196.561088 million received from Suzhou Fund,

The total existing registered capital of Xingyao Kunze held by Tianjin Fund is 3.086511 million yuan. As of the date of this announcement,

These transactions have not yet been completed.

10. Interpretation and meaning

Nature's Sunshine Products, Inc. (NASDAQ: NATR refers to City, stock code: NATR)

Based on the second phase of the incentive plan, Fosun Antkin made the second grant, This grant is to Mr. Chen Zhanyu at a price of 25.26 yuan/1 restricted equity. refer to This related transaction granted 111,000 restricted equity shares (corresponding to 111,000 shares of Fosun

Antkin shares)

The Company and Fosun Pharma refer to Shanghai Fosun Pharma (Group) Co., Ltd.

The Group refers to the Company and its holding subsidiaries/units

Chengdu Jinchengan refers to Chengdu Jinchengan Biotechnology Partnership (Limited Partnership) Chengdu Jinshian refers to Chengdu Jinshian Biotechnology Partnership (Limited Partnership)

Fosun Entejin (Chengdu) Biopharmaceutical Co., Ltd. (formerly known as

Fosun Antgene refers to Fosun Antgene (Chengdu) Biopharmaceutical Co., Ltd. in 2026

Changed to a joint stock company and changed its name in January)

The second tranche of Fosun Antkin was adopted by Fosun Antkin on August 27, 2024 and will be issued on January 1, 2026. Incentive Plan, Refer to the "Fosun Entejin (Chengdu) Biopharmaceutical Co., Ltd." revised on 15th March

Second Phase Incentive Plan Second Phase Equity Incentive Plan of Co., Ltd."

Fosun Antjin’s first phase of incentives will be adopted by Fosun Antjin on August 27, 2024 and will be implemented on January 1, 2026.

Plans and Instructions "Fosun Entejin (Chengdu) Biopharmaceutical Co., Ltd." revised on March 14

First Phase Incentive Plan Co., Ltd. First Phase Equity Incentive Plan》

Fosun Health refers to Shanghai Fosun Health Technology (Group) Co., Ltd. Fosun Carey refers to Fosun Carey (Shanghai) Biotechnology Co., Ltd.

Fosun Pingyao refers to Shanghai Fosun Pingyao Investment Management Co., Ltd.

Fosun Industrial refers to Fosun Industrial (Hong Kong) Co., Ltd.

Fosun Pharmaceutical Industry refers to Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.

Fosun Pharma (Shenzhen) refers to Fosun Pharma Industrial Development (Shenzhen) Co., Ltd.

Fuyao Qihang refers to Tianjin Fuyao Qihang Commercial Management Partnership (Limited Partnership)

Haina Pharmaceutical refers to Nanjing Haina Pharmaceutical Technology Co., Ltd.

Hangzhou Fuyao refers to Hangzhou Fuyao Enterprise Management Partnership (Limited Partnership)

Healthy Leasing refers to Fosun Healthy Financial Leasing (Shanghai) Co., Ltd. (cancelled)

Incentive platform refers to Chengdu Jinchengan and/or Chengdu Jinshian

Green Bamboo Biotechnology refers to Beijing Green Bamboo Biotechnology Co., Ltd.

Nanjing Fund refers to Nanjing Xingjian Ruiying Equity Investment Partnership (Limited Partnership)

Ningbo Fuying refers to Ningbo Fuying Investment Co., Ltd. Shanghai Rehabilitation refers to Shanghai Rehabilitation Equity Investment Fund Management Co., Ltd.

Shanghai Stock Exchange refers to Shanghai Stock Exchange

"Listing Rules" of Shanghai Stock Exchange refers to "Stock Listing Rules of Shanghai Stock Exchange"

Shenzhen Hengtai refers to Shenzhen Hengtai Biotechnology Co., Ltd.

Shenzhen Biomedical Industry Foundation Shenzhen Pengfu Biomedical Industry Private Equity Investment Fund Partnership refer to Gold industry (limited partnership) Synthetica Pioneering CO., LTD

Shengbao Biotechnology refers to Shenzhen Shengbao Biotechnology Co., Ltd.

Suzhou Fund refers to Suzhou Fuxian Xingyi Venture Capital Partnership (Limited Partnership)

Suzhou Angel Fund refers to Suzhou Xingshengyuanfeng Venture Capital Partnership (Limited Partnership)

Tide Pharmaceutical refers to Tide Pharmaceutical (Zhejiang) Co., Ltd.

Tianjin Fosun Haihe Medical and Health Industry Fund Partnership (Limited Partnership) Tianjin Fund refers to Guy) Hong Kong Stock Exchange refers to The Stock Exchange of Hong Kong Limited

Xingrui Jingxuan refers to Chengdu Xingrui Jingxuan Biotechnology Co., Ltd.

Xingsheng Fuying refers to Suzhou Xingsheng Fuying Enterprise Management Partnership (Limited Partnership)

Xingshuangjian Investment refers to Shanghai Xingshuangjian Investment Management Co., Ltd.

Xingshuangjian Medical refers to Shanghai Xingshuangjian Medical Investment Management Co., Ltd. Xingyao No. 2 refers to Xingyao No. 2 (Tianjin) Enterprise Management Partnership (Limited Partnership)

Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (formerly known as Suzhou

Xingyao Kunze refers to Xingyao Kunze Biopharmaceutical Co., Ltd., changed in December 2025

Become a joint stock company and change its name)

Yuan and ten thousand yuan refer to RMB and ten thousand yuan unless otherwise specified.

Capital increase and share expansion refer to June 15, 2026, Fosun Antjin and the Company’s holding companies

Four investors, including subsidiary Fosun Pharmaceutical Industries, signed an agreement

proposal, (which mainly includes) Fosun Antkin plans to sell shares at 84.207235

A total of 11,495,449 new issuances were issued to these investors at a price of RMB 11,495,449

shares

Announcement is hereby made.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

board of directors June 15, 2026